Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
(This article was published on October 21, 2020, at NEJM.org)
Here’s a podcast from GameChangers powered by CEimpact
COVID-19 Update: Convalescent Plasma and Tocilizumab
The efficacy of interleukin-6 receptor blockade in hospitalized patients with coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is unclear.
Tocilizumab was not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19. Some benefit or harm cannot be ruled out, however, because the confidence intervals for efficacy comparisons were wide. (Funded by Genentech; ClinicalTrials.gov number, NCT04356937.)
